RxDoctor Payments Data

Jayanta Das, MD

Interventional Cardiology · Mission Hills, CANPI 1891843827

Payments from drug & device makers

$29,870in general payments, 2019–2025

Across 460 payments — averaging $64.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • Bayer$3K
  • Abbott$2K
  • Novartis$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Merck$920
  • plus $4K from 27 others

What the payments were for

  • Speaking & faculty fees$18,24161%
  • Travel & lodging$1931%
  • Food & beverage$11,32338%
  • Education$1130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,870 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$302,431
Medicare patients
1,202
Services billed
3,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban261$301,471
EntrestoSacubitril/Valsartan174$251,834
FarxigaDapagliflozin Propanediol122$123,954
JardianceEmpagliflozin53$56,411
XareltoRivaroxaban41$55,659
Repatha SureclickEvolocumab51$54,713
BrilintaTicagrelor17$18,881
Metoprolol Succinate413$7,935
Rosuvastatin Calcium289$4,401
Atorvastatin Calcium286$3,256
Ranolazine ErRanolazine28$2,558
Losartan Potassium203$2,544
Icosapent Ethyl16$1,986
Nitroglycerin92$1,159
Amlodipine Besylate166$1,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$401$301,471261 claims
NovartisEntresto$1,594$251,834174 claims
AstraZenecaFarxiga, Brilinta$16,758$142,835139 claims
Boehringer IngelheimJardiance$480$56,41153 claims
Johnson & JohnsonXarelto$133$55,65941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →